MY172458A - Therapeutic agent or prophylactic agent for dementia - Google Patents
Therapeutic agent or prophylactic agent for dementiaInfo
- Publication number
- MY172458A MY172458A MYPI2014703534A MYPI2014703534A MY172458A MY 172458 A MY172458 A MY 172458A MY PI2014703534 A MYPI2014703534 A MY PI2014703534A MY PI2014703534 A MYPI2014703534 A MY PI2014703534A MY 172458 A MY172458 A MY 172458A
- Authority
- MY
- Malaysia
- Prior art keywords
- agent
- therapeutic agent
- dementia
- prophylactic
- prophylactic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a novel therapeutic agent or prophylactic agent for cognitive disorders. [SOLUTION MEANS] The invention provides an antibody that participates in antigen-antibody reaction specifically with tau protein that has been phosphorylated in the vicinity of Ser413 of SEQ ID NO: 1, and a therapeutic agent or prophylactic agent for cognitive disorders comprising as an active ingredient a peptide that has been phosphorylated in the vicinity of Ser413.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012124336 | 2012-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY172458A true MY172458A (en) | 2019-11-26 |
Family
ID=49673425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014703534A MY172458A (en) | 2012-05-31 | 2013-05-30 | Therapeutic agent or prophylactic agent for dementia |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20150183854A1 (en) |
| EP (2) | EP2857039B1 (en) |
| JP (3) | JP5971659B2 (en) |
| KR (2) | KR102208283B1 (en) |
| CN (1) | CN104602708B (en) |
| AR (1) | AR091218A1 (en) |
| AU (2) | AU2013268364B2 (en) |
| BR (1) | BR112014029566A2 (en) |
| CA (1) | CA2875205C (en) |
| CY (1) | CY1122530T1 (en) |
| DK (1) | DK2857039T3 (en) |
| ES (2) | ES2763361T3 (en) |
| HR (1) | HRP20192267T1 (en) |
| HU (1) | HUE046919T2 (en) |
| IL (1) | IL235899B (en) |
| LT (1) | LT2857039T (en) |
| ME (1) | ME03587B (en) |
| MX (1) | MX361128B (en) |
| MY (1) | MY172458A (en) |
| NZ (1) | NZ630536A (en) |
| PH (1) | PH12014502669B1 (en) |
| PL (1) | PL2857039T3 (en) |
| PT (1) | PT2857039T (en) |
| RS (1) | RS59802B1 (en) |
| RU (1) | RU2657438C2 (en) |
| SG (2) | SG11201407878VA (en) |
| SI (1) | SI2857039T1 (en) |
| TW (2) | TWI777183B (en) |
| WO (1) | WO2013180238A1 (en) |
| ZA (1) | ZA201409186B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| EP2709728B1 (en) * | 2011-05-20 | 2019-01-23 | Oligomerix, Inc. | Tau protease methods of use |
| PL2857039T3 (en) * | 2012-05-31 | 2020-05-18 | Osaka City University | Therapeutic agent or prophylactic agent for dementia |
| HK1209768A1 (en) | 2012-07-03 | 2016-04-08 | Washington University | Antibodies to tau |
| TWI664190B (en) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | Humanized anti-tau antibodies |
| EP3448875A4 (en) * | 2016-04-29 | 2020-04-08 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
| JP6785372B2 (en) * | 2016-09-30 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | SPR-based double bond assay for functional analysis of multispecific molecules |
| BR112019017021A2 (en) | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anti-tau antibodies and methods of using them |
| JP2018139530A (en) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same |
| BR112019022789A2 (en) | 2017-05-30 | 2020-06-09 | Teijin Pharma Ltd | anti-igf-i receptor antibody or fragment thereof or a derivative thereof, nucleic acid molecule, cloning vector or expression vector, recombinant cell, process of producing an anti-igf-i receptor antibody or fragment thereof or a derivative thereof, pharmaceutical composition, medication, method for growing cells derived from vertebrates in vitro, and, transgenic animal. |
| AU2018345523B2 (en) | 2017-10-02 | 2021-10-21 | Merck Sharp & Dohme Llc | Chromane monobactam compounds for the treatment of bacterial infections |
| EP3697814A1 (en) | 2017-10-16 | 2020-08-26 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| EP3778631A4 (en) | 2018-04-06 | 2022-01-05 | Teijin Pharma Limited | SPNS2 NEUTRALIZING ANTIBODY |
| EP3819378A4 (en) | 2018-07-04 | 2022-09-14 | Aichi Medical University | OLIGONUCLEOTIDES FOR REGULATING TAU PROTEIN SPLICING, AND THEIR USES |
| CN110028583B (en) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | Anti-Tau antibody and its application in the treatment of Alzheimer's disease and traumatic brain injury |
| GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| JP7429404B2 (en) * | 2019-08-06 | 2024-02-08 | 慶應義塾 | Method for producing tau-related disease models |
| WO2021065306A1 (en) | 2019-09-30 | 2021-04-08 | ニプロ株式会社 | Method for detecting tau protein using blood sample as specimen |
| JP2023518281A (en) | 2020-03-19 | 2023-04-28 | ヴァスキュラー バイオサイエンスィズ | CAR peptides for improving coronavirus survival |
| CA3183835A1 (en) | 2020-06-25 | 2021-12-30 | Jeanne E. Baker | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CA3266790A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (en) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | arc |
| JP3587390B2 (en) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | Phosphorylated amino acid derivative and phosphorylated peptide synthesis method |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| EP2028932A4 (en) * | 2006-06-16 | 2011-10-12 | Vitruvean Llc | TRANSGENIC FLUIDS EXPRESSING A PRECURSOR FRAGMENT OF AMYLOID AND TAU PROTEIN |
| UA107571C2 (en) * | 2009-04-03 | 2015-01-26 | PHARMACEUTICAL COMPOSITION | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CA3239368A1 (en) * | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| US8703137B2 (en) * | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| TR201102696U (en) * | 2011-05-27 | 2011-06-21 | Turhal Sal�H | Freestanding moving product advertising stand. |
| PL2857039T3 (en) * | 2012-05-31 | 2020-05-18 | Osaka City University | Therapeutic agent or prophylactic agent for dementia |
| JP2018139530A (en) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same |
-
2013
- 2013-05-30 PL PL13797290T patent/PL2857039T3/en unknown
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/en not_active Application Discontinuation
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 SI SI201331636T patent/SI2857039T1/en unknown
- 2013-05-30 MX MX2014014187A patent/MX361128B/en active IP Right Grant
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/en active Active
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/en active Active
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/en active
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 ES ES13797290T patent/ES2763361T3/en active Active
- 2013-05-30 TW TW109121902A patent/TWI777183B/en active
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/en unknown
- 2013-05-30 PT PT137972907T patent/PT2857039T/en unknown
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/en unknown
- 2013-05-30 TW TW102119176A patent/TWI700296B/en active
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/en active
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/en active Active
- 2013-05-30 HR HRP20192267TT patent/HRP20192267T1/en unknown
- 2013-05-30 ES ES19207405T patent/ES2973070T3/en active Active
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 AR ARP130101907 patent/AR091218A1/en active IP Right Grant
- 2013-05-30 RS RS20191640A patent/RS59802B1/en unknown
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/en unknown
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/en active Active
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/en not_active Ceased
-
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
-
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/en active Active
-
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/en active Active
-
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/en unknown
-
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY172458A (en) | Therapeutic agent or prophylactic agent for dementia | |
| PH12017501417A1 (en) | Anti-fap antibodies and methods of use | |
| MY156697A (en) | Modified tuberculosis antigens | |
| NZ630542A (en) | Methods of treating a tauopathy | |
| MX2014015002A (en) | Polypeptides having transgalactosylating activity. | |
| MX2015006324A (en) | Methods for the manufacture of proteolytically processed polypeptides. | |
| WO2011113019A3 (en) | Ctla4 proteins and their uses | |
| MY160552A (en) | Low protein infant formula with increased essential amino acids | |
| MX393988B (en) | Interferon î±2b variants | |
| MX2020010399A (en) | 3-epimerase. | |
| WO2013123432A3 (en) | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases | |
| MX2014001372A (en) | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer. | |
| SG10201804385YA (en) | Stimulus responsive polymers for the purification of biomolecules | |
| MX2015001083A (en) | Modified factor x polypeptides and uses thereof. | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| MX368288B (en) | Combinations and uses thereof. | |
| EP4306174A3 (en) | Composition for controlled ovarian stimulation | |
| HK1212995A1 (en) | A method of purifying proteins | |
| EP2552462A4 (en) | CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE | |
| IN2014DN10209A (en) | ||
| WO2013101509A3 (en) | Hsp70 fusion protein conjugates and uses thereof | |
| WO2013166183A3 (en) | Replikin sequences and their antibodies, therapeutics and vaccines against prion and neurodegenerative disorders | |
| GB201114923D0 (en) | Immunogenic proteins and compositions | |
| WO2011156694A3 (en) | Enrichment and purification of infectious prion proteins | |
| TH154070A (en) | Therapeutic or preventive substances for dementia |